Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Duke Clinical Research Institute, Durham, NC, USA.
Europace. 2018 Oct 1;20(10):1621-1629. doi: 10.1093/europace/euy183.
Implantable cardioverter-defibrillators (ICDs) are key in the prevention of sudden cardiac death, but outcomes may vary by type of device or programming [single chamber (SC) vs. dual chamber (DC)] in patients without a bradycardia pacing indication. We sought to meta-analyse patient outcomes of randomized trials of SC vs. DC devices or programming.
We searched PubMed, Embase, Scopus, Web of Science, and Cochrane trials databases for relevant studies excluding those published before 2000, involving children, or not available in English. Endpoints included mortality, inappropriate ICD therapies, and implant complications. Endpoints with at least three reporting studies were meta-analysed. We identified eight studies meeting inclusion criteria representing 2087 patients with 16.1 months mean follow-up. Mean age was 62.7 years (SD 1.92); in six studies reporting sex, most patients were male (85%). Comparing patients with a SC or DC ICD or programming, we found similar rates of mortality [odds ratio (OR) 0.95, 95% confidence interval (CI) 0.54-1.68; P = 0.86] and inappropriate therapies (OR 1.46, 95% CI 0.97-2.19; P = 0.07) in five and six studies, respectively. In three studies of SC vs. DC ICDs (but not programming) rates of pneumothorax and lead dislodgement were not different (OR 2.12, 95% CI 0.18-24.72; P = 0.55 and OR 0.87, 95% CI 0.32-2.47; P = 0.83, respectively).
In this meta-analysis of randomized controlled trials comparing SC vs. DC ICD device or programming, there was no significant difference in inappropriate therapies, mortality, pneumothorax, or lead dislodgement. Future studies should compare these devices over longer follow-up and in specific patient populations.
植入式心脏复律除颤器(ICD)在预防心脏性猝死方面发挥着关键作用,但在没有心动过缓起搏指征的患者中,不同类型的设备或程控(单腔 [SC] 与双腔 [DC])可能会导致不同的结果。我们旨在对 SC 与 DC 设备或程控的随机试验患者结局进行荟萃分析。
我们检索了 PubMed、Embase、Scopus、Web of Science 和 Cochrane 临床试验数据库,排除了 2000 年前发表的、涉及儿童的或英文不可用的研究。研究终点包括死亡率、不恰当的 ICD 治疗和植入并发症。至少有 3 项报告研究的终点进行了荟萃分析。我们确定了 8 项符合纳入标准的研究,共纳入 2087 例患者,平均随访 16.1 个月。患者平均年龄为 62.7 岁(标准差 1.92);在 6 项报告性别情况的研究中,大多数患者为男性(85%)。比较 SC 或 DC ICD 或程控患者,我们发现死亡率[比值比(OR)0.95,95%置信区间(CI)0.54-1.68;P=0.86]和不恰当治疗率[OR 1.46,95% CI 0.97-2.19;P=0.07]在 5 项和 6 项研究中相似。在 3 项 SC 与 DC ICD 研究中(但编程研究中没有),气胸和导联脱位的发生率没有差异[OR 2.12,95% CI 0.18-24.72;P=0.55 和 OR 0.87,95% CI 0.32-2.47;P=0.83,分别]。
在这项比较 SC 与 DC ICD 设备或程控的随机对照试验荟萃分析中,不恰当的治疗、死亡率、气胸或导联脱位之间无显著差异。未来的研究应在更长的随访时间和特定的患者人群中比较这些设备。